$153 Million is the total value of Consonance Capital Management LP's 15 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 23.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TNDM | Sell | TANDEM DIABETES CARE INC | $45,256,000 | -22.2% | 300,664 | -38.3% | 29.52% | -7.3% |
| GMED | Sell | GLOBUS MED INCcl a | $26,949,000 | -40.3% | 373,254 | -36.6% | 17.58% | -28.8% |
| Buy | SURROZEN INC | $22,359,000 | +232.8% | 3,497,500 | +249.8% | 14.58% | +296.7% | |
| SLN | Buy | SILENCE THERAPEUTICS PLCads | $18,115,000 | +385.8% | 758,253 | +324.1% | 11.82% | +478.9% |
| UTHR | Sell | UNITED THERAPEUTICS CORP DEL | $12,930,000 | -55.6% | 59,838 | -62.1% | 8.43% | -47.1% |
| CMPX | New | COMPASS THERAPEUTICS INC | $11,165,000 | – | 3,500,000 | +100.0% | 7.28% | – |
| RACB | RESEARCH ALLIANCE CORP II | $2,931,000 | -0.8% | 300,000 | 0.0% | 1.91% | +18.2% | |
| JYAC | JIYA ACQUISITION CORP | $2,931,000 | +0.1% | 300,000 | 0.0% | 1.91% | +19.4% | |
| MSAC | MEDICUS SCIENCES ACQUISITION | $2,916,000 | -0.3% | 300,000 | 0.0% | 1.90% | +18.8% | |
| ARYA SCIENCES ACQUISITN CORP | $2,910,000 | -1.8% | 300,000 | 0.0% | 1.90% | +17.0% | ||
| PANA | PANACEA ACQUISITION CORP II | $1,940,000 | -0.7% | 200,000 | 0.0% | 1.26% | +18.3% | |
| HLXA | HELIX ACQUISITION CORP | $1,484,000 | -0.3% | 150,000 | 0.0% | 0.97% | +18.8% | |
| Buy | SURROZEN INC*w exp 08/01/203 | $1,331,000 | +268.7% | 1,165,832 | +249.7% | 0.87% | +338.4% | |
| CMAXW | CAREMAX INC*w exp 06/08/202 | $64,000 | -52.2% | 45,960 | 0.0% | 0.04% | -42.5% | |
| MSACW | MEDICUS SCIENCES ACQUISITION*w exp 02/12/202 | $24,000 | 0.0% | 33,331 | 0.0% | 0.02% | +23.1% | |
| CASI | Exit | CASI PHARMACEUTICALS INC | $0 | – | -1,563,003 | -100.0% | -1.02% | – |
| OLK | Exit | OLINK HLDG ABsponsored ads | $0 | – | -115,425 | -100.0% | -1.53% | – |
| SWTX | Exit | SPRINGWORKS THERAPEUTICS INC | $0 | – | -305,994 | -100.0% | -10.62% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UNITED THERAPEUTICS CORP DEL | 29 | Q2 2022 | 15.9% |
| ADMA BIOLOGICS INC | 27 | Q4 2020 | 2.3% |
| RETROPHIN INC | 23 | Q1 2020 | 11.3% |
| ANI PHARMACEUTICALS INC | 23 | Q3 2019 | 7.9% |
| VERICEL CORP | 21 | Q4 2019 | 5.5% |
| AMARIN CORP PLC | 14 | Q3 2019 | 14.4% |
| GLOBUS MED INC | 13 | Q2 2022 | 24.7% |
| ORTHOFIX INTL N V | 13 | Q3 2016 | 9.7% |
| PACIFIC BIOSCIENCES CALIF IN | 13 | Q4 2018 | 9.7% |
| CATALYST PHARM PARTNERS INC | 13 | Q3 2019 | 9.4% |
View Consonance Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Surrozen, Inc./DESold out | December 15, 2022 | 0 | 0.0% |
| ADMA BIOLOGICS, INC. | February 14, 2022 | 1,289,481 | 1.4% |
| ASSEMBLY BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| CASI Pharmaceuticals, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Cellectar Biosciences, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Gamida Cell Ltd.Sold out | February 14, 2022 | 0 | 0.0% |
| GenMark Diagnostics, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Protagonist Therapeutics, IncSold out | February 14, 2022 | 0 | 0.0% |
| Sio Gene Therapies Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Consonance-HFW Acquisition Corp. | April 27, 2021 | 1,000,000 | 10.4% |
View Consonance Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2022-12-15 |
| SC 13D/A | 2022-12-15 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
View Consonance Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.